[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,903
  • Shares Outstanding, K 119,354
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,760 K
  • EBIT $ -33 M
  • EBITDA $ -33 M
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings $-0.08 on 05/14/26
  • Next Earnings Date 08/14/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 2
  • High Estimate $-0.06
  • Low Estimate $-0.07
  • Prior Year $-0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7910 +17.43%
on 07/08/26
1.0800 -13.99%
on 07/13/26
+0.1259 (+15.68%)
since 06/12/26
3-Month
0.7700 +20.64%
on 05/20/26
1.1850 -21.61%
on 04/22/26
-0.1211 (-11.53%)
since 04/13/26
52-Week
0.7700 +20.64%
on 05/20/26
1.5100 -38.48%
on 09/29/25
-0.2511 (-21.28%)
since 07/11/25

Most Recent Stories

More News
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential...

ONCY : 0.9289 (+4.69%)
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Intellectual property update confirms pelareorep’s unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional...

ONCY : 0.9289 (+4.69%)
Wall Street May Still Be Looking at the Old Oncolytics Story

Oncolytics Biotech is gaining attention as pelareorep shows encouraging results in multiple cancers, positioning the company as a potentially valuable player in the growing immunotherapy market.

ONCY : 0.9289 (+4.69%)
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically...

ONCY : 0.9289 (+4.69%)
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial...

ONCY : 0.9289 (+4.69%)
Stocks in play: Oncolytics Biotech Inc

Announces that translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American ...

ONCY : 0.9289 (+4.69%)
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced translational...

ONCY : 0.9289 (+4.69%)
Stocks in play: Oncolytics Biotech Inc

Announced new durability data in metastatic colorectal cancer, demonstrating meaningful and sustained ...

ONCY : 0.9289 (+4.69%)
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in...

ONCY : 0.9289 (+4.69%)
Stocks in play: Oncolytics Biotech Inc

Announces that a Type C meeting with the U.S. Food and Drug Administration has resulted in alignment ...

ONCY : 0.9289 (+4.69%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.2326
2nd Resistance Point 1.1563
1st Resistance Point 1.0426
Last Price 0.9289
1st Support Level 0.8526
2nd Support Level 0.7763
3rd Support Level 0.6626

See More

52-Week High 1.5100
Fibonacci 61.8% 1.2273
Fibonacci 50% 1.1400
Fibonacci 38.2% 1.0527
Last Price 0.9289
52-Week Low 0.7700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.